Illuminated microcatheter significantly lowers IOP in trabeculotomy

Article

Circumferential trabeculotomy performed with an illuminated microcatheter causes a significant reduction in IOP in glaucoma patients.

Circumferential trabeculotomy performed with an illuminated microcatheter causes a significant reduction in IOP in glaucoma patients, according to a study featured in the Journal of Glaucoma.

Dr C.A. Girkin et al., Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Alabama, USA, conducted a retrospective chart study on 11 eyes from 7 patients with primary or secondary congenital or juvenile glaucoma.

All patients underwent circumferential trabeculotomy with an illuminated microcatheter and eyes with six or more months of IOP data were included in the study. An IOP of lower than 21 mmHg was considered a success and a 30% IOP reduction without the use of IOP-lowering medications was also considered a success.

Mean IOP was 33.8±6.3 preoperatively and 18.3±3.5 at the final postoperative follow-up visit. Qualified success was demonstrated in 90.1% of eyes and unqualified success was reported in 81.8% of eyes. There were no long-term surgical complications.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.